Enjoy complimentary customisation on priority with our Enterprise License!
The non-hodgkin lymphoma (NHL) therapeutics market size is forecast to increase by USD 6.96 billion at a CAGR of 9.45% between 2023 and 2028. The market is experiencing significant advancements, driven by recent approvals and a strong pipeline. The introduction of innovative treatments, such as intensity-modulated radiation therapy (IMRT) and proton therapy, is transforming the landscape of NHL treatment. IMRT enables precise delivery of radiation to the tumor site, reducing damage to healthy cells. Proton therapy, an advanced form of radiation therapy, offers even greater precision and reduced side effects. Two major categories of NHL, T-cell and B-cell lymphomas, are benefiting from these advancements. T-cell lymphomas, which are less responsive to conventional chemotherapy, are being addressed through targeted therapies. B-cell lymphomas, the most common type, are being treated with monoclonal antibodies and immunotherapies. However, the market faces challenges, including the adverse effects of available therapeutics and the high cost of these advanced treatments. Addressing these challenges will require continued research grants and funding to develop more effective and affordable treatments. By focusing on these areas, the NHL therapeutics market is poised for continued growth and innovation.
_therapeutics_market_size_abstract_2024_v1.jpg?format=webp)
Non-Hodgkin Lymphoma (NHL) is a type of hematologic malignancy, accounting for approximately 45% of all newly diagnosed lymphomas. The disease manifests through the abnormal proliferation of lymphocytes, leading to the formation of tumors in lymph nodes and other organs. The NHL therapeutics market is witnessing significant advancements due to the introduction of novel treatment modalities, including chemotherapy, targeted therapies, and immunotherapy. Chemotherapy remains a cornerstone of NHL treatment, with alkylating agents, anthracyclines, and corticosteroids being the most commonly used drugs. However, the side effects associated with chemotherapy, such as myelosuppression and neurotoxicity, necessitate the exploration of alternative therapeutic approaches.
Additionally, targeted therapies have emerged as a promising treatment modality for NHL. These therapies aim to inhibit specific molecular targets involved in the disease progression, thereby minimizing the adverse effects of chemotherapy. Monoclonal antibodies, such as rituximab, are widely used targeted therapies in NHL treatment. Immunotherapy, another innovative therapeutic approach, harnesses the power of the immune system to target and eliminate cancer cells. Chimeric antigen receptor (CAR) T-cell therapies, such as lisocabtagene maraleucel and axicabtagene ciloleucel, have shown remarkable efficacy in the treatment of relapsed or refractory NHL. Radiation therapy, including intensity-modulated radiation therapy (IMRT), plays a crucial role in the management of localized NHL.
Moreover, IMRT allows for precise delivery of radiation doses to the tumor site while minimizing exposure to healthy tissues. The NHL therapeutics market is witnessing significant research and development activities. For instance, the Oncology Journal published a study on the efficacy of ueFI technology platform in improving the response rate of NHL patients to chemotherapy. Similarly, UExcel technology platform is being explored for its potential in enhancing the efficacy of radiotherapy in NHL treatment. The growing number of NHL cases and the increasing demand for personalized and effective treatment options are expected to drive the growth of the NHL therapeutics market.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The hospital pharmacy segment is estimated to witness significant growth during the forecast period. The market is primarily driven by the increasing usage of advanced treatment modalities, such as CAR T-cell therapy. This innovative approach targets genetic mutations and abnormalities in signaling pathways, which are characteristic of various molecular subtypes of NHL. Hospital pharmacies hold the largest market share in the NHL therapeutics industry due to their central role in procuring, storing, compounding, dispensing, manufacturing, testing, packaging, and distributing drugs. Pharmacists in these settings are responsible for ensuring the safe and effective use of medications, acting as a bridge between patients and healthcare providers, and providing drug information to the public. The hospital pharmacy segment is further segmented into in-patient and out-patient drug distribution systems. Regardless of the distribution system, hospital pharmacists play a crucial role in optimizing patient care by facilitating appropriate medication use and enhancing patient understanding of their treatment plans.
_Therapeutics_Market_segments_abstract_2024_v2.jpg?format=webp)
Get a glance at the market share of various segments Request Free Sample
The hospital pharmacy segment accounted for USD 3.70 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
_therapeutics_market_regions_abstract_2023_geo_v2.jpg?format=webp)
For more insights on the market share of various regions Request Free Sample
The market in North America is experiencing significant growth due to the increasing number of approved treatments for various subtypes of NHL and the rising prevalence of hematologic cancers, including NHL. According to the National Program of Cancer Registries (NPCR), carried out by the Centers for Disease Control and Prevention (CDC), over 28.5 million invasive cancer cases have been diagnosed in the last two decades, with over one million new cases reported annually. NHL is the eighth most common cancer type in the US, making it a major market contributor in North America. Two of the latest advancements in NHL drug therapy are C-CAR039 and Lisocabtagene maraleucel.
Moreover, C-CAR039 is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD123, a protein overexpressed in certain types of NHL. On the other hand, Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory large B-cell lymphoma and follicular lymphoma. Advanced technologies, such as the uAIFI Technology Platform and uExcel Technology Platform, are also contributing to the growth of the NHL therapeutics market. These platforms enable the development of more effective and personalized treatments, which can lead to improved patient outcomes. In conclusion, the increasing incidence of NHL and the availability of innovative therapeutics, such as C-CAR039 and Lisocabtagene maraleucel, along with advanced technologies, are driving the growth of the NHL therapeutics market in North America.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Recent approvals and a strong pipeline are the key drivers of the market. In the realm of oncology, the non-Hodgkin lymphoma (NHL) disease market represents a significant area of focus due to the increasing number of cancer cases. Traditionally, chemotherapy has been the primary treatment option for various types of NHL. However, the landscape is evolving as targeted therapies and immunotherapies gain traction. This shift is driven by the limitations of chemotherapy, including long-term side effects that impact patient adherence.
In the NHL therapeutics market, these advanced treatments hold a larger share compared to chemotherapies. Despite advancements, opportunities remain for enhancing the pharmacokinetics and pharmacodynamics of treatments for advanced or metastatic lymphomas, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL). As healthcare systems and providers continue to seek effective and patient-friendly treatment options, the focus on targeted therapies and immunotherapies is expected to persist.
Research grants and funding are the upcoming trends in the market. Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects B cells, a type of white blood cell. The current market for NHL therapeutics is populated by approved treatments from established pharmaceutical companies. However, the pipeline exhibits a diverse range of innovative drugs under development by both large and small pharmaceutical entities. These smaller companies are actively conducting clinical trials, yet they face funding challenges in completing their research. Leading research institutions are also actively engaged in the development of advanced therapies for various types of lymphomas, including NHL. These organizations rely on grants from various funding sources to finance their research.
For instance, Bloodwise, a UK-based blood cancer research charity, supports research institutes and small pharmaceutical companies in their quest to discover and develop treatments for blood cancers, including NHL therapeutics. The NHL therapeutics market is currently dominated by large pharmaceutical companies, with several small and medium-sized entities contributing to the pipeline. These smaller companies bring novel molecules to the table but often lack the necessary resources to bring them to market. As research continues, the potential for new treatments and advancements in the field of NHL therapeutics remains promising.
Adverse effects of available therapeutics are key challenges affecting the market growth. Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system. The current treatment landscape for NHL includes various chemotherapies, monoclonal antibodies, and radiation therapy. Radiation therapy plays a crucial role in treating localized lymphomas. Two common types of radiation therapy are intensity-modulated radiation therapy (IMRT) and proton therapy. IMRT is a type of external beam radiation therapy that delivers precise doses of radiation to the tumor while minimizing exposure to healthy cells. Proton therapy is a more advanced form of radiation therapy that uses protons instead of X-rays to destroy cancer cells. Both therapies have shown promising results in treating NHL.
However, the use of chemotherapies, including REVLIMID, RITUXIMAB, and VELCADE, in treating NHL is not without side effects. These drugs are associated with a range of adverse effects, such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. Some less common side effects include constipation, blurred vision, and skin reactions. REVLIMID, for instance, may cause low blood count, diarrhea, itching, and rash, among other side effects. RITUXIMAB can lead to black, tarry stools, bleeding gums, and blistering or peeling of the skin. VELCADE may cause peripheral neuropathy, nausea, and vomiting, among other side effects. Despite their efficacy, these drugs can significantly impact a patient's quality of life due to their side effects.
Therefore, it is essential to weigh the benefits against the risks before deciding on a treatment plan. A multidisciplinary approach involving oncologists, radiation therapists, and other healthcare professionals is crucial in managing the side effects and optimizing treatment outcomes for patients with NHL.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
_therapeutics_market_customer_landscape_abstract_2023_geo_v1.jpg?format=webp)
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca Plc - The company offers non-Hodgkin lymphoma therapeutics such as T-cell engagers which are bispecific molecules that are engineered to redirect the immune systems to recognize and kill cancer cells.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Non-Hodgkin Lymphoma (NHL) is a type of hematologic malignancy characterized by the uncontrolled proliferation of abnormal lymphocytes. The therapeutic landscape for NHL is diverse and includes chemotherapy, targeted therapies, and immunotherapy. Chemotherapy remains a mainstay treatment for many NHL subtypes, while targeted therapies and immunotherapies are increasingly being used to address genetic mutations and molecular subtypes. Signaling pathways and genetic abnormalities play a crucial role in the development and progression of NHL. Diagnostic techniques, such as molecular testing and imaging, aid in identifying the specific subtypes and guiding treatment decisions. Precision medicine and healthcare policies are driving the development of new NHL drugs, including CAR T-cell therapies like C-CAR and Lisocabtagene Maraleucel, and monoclonal antibodies like Rituximab.
Pharmaceutical companies and research institutions are at the forefront of advancing NHL therapeutics, with ongoing research focusing on immune checkpoint inhibitors and novel targeted therapies. Radiation therapy, including intensity-modulated radiation therapy and proton therapy, also plays a role in the treatment of localized NHL. Healthcare systems and providers offer various treatment options, including hospital pharmacies and online pharmacies, for administering NHL drugs. The Oncology Journal and other publications provide valuable insights into the latest research and advancements in NHL therapeutics. Axicabtagene Ciloleucel and other emerging NHL drugs offer hope for patients, although toxicities associated with these therapies remain a concern. B cell lymphomas and T cell lymphomas are the two main categories of NHL, with B cells being the most common type. Understanding the unique characteristics of each subtype is essential for effective treatment and improving patient outcomes.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
190 |
|
Base year |
2023 |
|
Historic period |
2017-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.45% |
|
Market growth 2024-2028 |
USD 6.96billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.42 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 46% |
|
Key countries |
US, UK, Germany, China, and Canada |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
